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Growth Differ 2007;49:583–9.Tricuspid Regurgitation Severity Associated
With Positioning of RV Lead or Other Etiology
Assessed by Intracardiac EchocardiographyWe read with interest the report by Mediratta et al. (1),
which concluded that an intercommissural or middle-
of-the-annulus position is desired to minimize
device-related tricuspid regurgitation (TR) post-
implantation of right ventricle (RV) pacemaker and
implantable cardioverter-deﬁbrillator (ICD) leads.
In their methodology, the RV lead location is deter-
mined by 3-dimensional (3D) transthoracic echocar-
diography (TTE) and the severity of TR, only by
2-dimensional (2D) color Doppler evaluation. Finally,
they suggested that 3D TTE should be routinely used
during intraprocedural lead placement. Several im-
portant issues, especially factors related to assess-
ment of the severity of TR in this retrospective study,
need to be clariﬁed.
Although not considered by Mediratta et al. (1),
causes of TR other than lead placement may be crit-
ical. TR may be due to either intrinsic valvular dis-
ease/dysfunction (leaﬂet, chord, or papillary muscle)
or tricuspid annulus enlargement. For patients withcardiac devices, the most frequent change in RV
morphology is dilation due to chronic elevation
of left heart ﬁlling pressures and subsequent devel-
opment of pulmonary hypertension. When pulmo-
nary artery systolic pressure (PASP) exceeds 40
mm Hg, the incidence of TR approaches 90% (2). Due
to lack of focus during retrospective analysis on
etiological factors and time interval dependence
between device implantation and 3D TTE study, one
could question whether TR is caused by underlying
heart disease or lead location. In their Figures 1
and 4 (1), moderate-to-severe RV dysfunction was
apparent in an example of septal impingement by a
device lead, whereas a normal/smaller RV chamber
was shown in their example (Figure 5) (1) of a well-
positioned lead. There must be other factors
involved; otherwise, what would explain the greater
baseline severity of TR in the lead impingement
group as shown in their Figure 6 (1)? Paired compar-
ison data for the subgroup patients with 2D TTE
before and after implantation (n ¼ 53) should have
been shown separately.
With routine clinical application of intracardiac
echocardiography (ICE), RV anatomy and function (3)
and many of the valvular etiologies of TR can be
identiﬁed and assessed in real time. Real-time ICE
imaging has superior capability to image the course of
the device lead from the right atrium to the RV. The
device-lead location and route passing through the
annulus can be imaged. TR induced by in-
tracardiac device-lead impingement and its severity
can be accurately assessed (Figures 1A and 1B). How-
ever, independent of lead position, moderate-to-
severe and mainly centralized TR can be commonly
detected in an enlarged and dysfunctional RV, sec-
ondary to left ventricular (LV) dysfunction/heart
failure (Figures 1C and 1D) or due to arrhythmogenic
RV cardiomyopathy (Figures 1E and 1F) with recurrent
ventricular tachyarrhythmia. It is strange that this
paper found no difference in TR severity in ICD
versus pacemaker lead implantation. Our clinical ob-
servations with ICE imaging may indicate that ICD
leads with more thickness and rigidity have higher
events of TR than standard pacing leads, as others
have reported previously (4).
Iatrogenic lead–related TR is an important clinical
problem, and the investigators should be congratu-
lated for reporting a relatively large number of cases
with 2D and 3D TTE imaging. However, their results
do not consider other important causes for TR and
certainly did not demonstrate convincingly how
real-time 3D TTE would consistently facilitate lead
placement.
FIGURE 1 Intracardiac Echocardiographic Images of Intracardiac Device Lead and Tricuspid Regurgitant Severity
With Different Etiologies
Intracardiac echocardiographic imaging with the transducer placed in the right atrium in 3 patients. The ﬁrst patient had severe left ventricular
(LV) dysfunction (left ventricular ejection fraction [LVEF] ¼ 20%), normal right ventricular (RV) size, and pulmonary artery systolic pressure
(PASP) estimated at 55 mm Hg, an implantable cardioverter deﬁbrillator (ICD) lead (arrow) placed at the RV anterolateral wall with
impingement of the posterior leaﬂet (A), and moderately eccentric tricuspid regurgitation (TR) with color Doppler imaging (CDI) (B). The
second patient had moderate LV dysfunction (LVEF ¼ 35%); enlarged RV and tricuspid annulus; PASP of 51 mm Hg; an ICD lead (rightward
arrows) placed at the RV apex; multiple small thrombi (leftward arrow) attached at the lead (C); and severely centralized TR with CDI, which
shows that the lead (arrows) is slightly impinging the posterior leaﬂet (D). The third patient had arrhythmogenic RV cardiomyopathy, enlarged
RV and tricuspid annulus, PASP of 33 mm Hg, LVEF ¼ 30%, a centralized location of ICD lead (arrows) placed at the RV apex (E), and
moderately to severely centralized TR with CDI (F). Ao ¼ aortic root; RA ¼ right atrium; RVOT ¼ RV outﬂow tract; tv ¼ tricuspid valve.
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by Intracardiac EchocardiographyWewould like to thank Dr. Ren and colleagues for their
interest and feedback and appreciate the opportunity
to reply. Themain limitation of our study (1) is that it is
retrospective; therefore, assumptions of cause and
effect regarding tricuspid regurgitation (TR) are
